The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Advice for community physicians managing Richter’s transformation of CLL
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, provides guidance on managing patients with Richter’s transformation (RT) of chronic lymphocytic leukemia (CLL). He stresses the significance of seeking advice from experienced clinicians and exploring enrollment in clinical trials and novel therapies. Prof. Ansell advises against relying solely on aggressive chemotherapy, which has historically yielded poor outcomes. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
